Feti Rahmawati is a doctoral student at the Faculty of Pharmacy, Universitas Gadjah Mada (UGM), Indonesia, with a research focus on drug discovery, molecular pharmacology, and the development of natural product–derived therapeutic candidates. Her PhD project investigates several synthetic curcumin analogues particularly dibenzylidene-cyclohexanone series as promising agents for rheumatoid arthritis. Integrating in silico, in vitro, and in vivo approaches, her work explores molecular interactions through docking and molecular dynamics simulations, followed by functional validation in macrophage models using assays such as nitric oxide inhibition, wound healing, MTT cytotoxicity, and qRT-PCR for inflammatory mediators. Her preclinical studies employ the Collagen-Induced Arthritis (CIA) mouse model to evaluate therapeutic outcomes through clinical scoring, histopathology, immunohistochemistry, ELISA biomarkers, and immunological modulation of the Th17/Treg axis. This multilayered strategy aims to clarify the anti-inflammatory, anti-destructive, and immunomodulatory mechanisms of curcumin analogues targeting key pathways in rheumatoid arthritis. Affiliated with the Curcumin Research Center (CRC) UGM, Feti contributes to interdisciplinary research involving medicinal chemistry, computational biology, and immunopharmacology. Her long-term interest lies in advancing innovative natural product–based drug development, particularly for autoimmune and inflammatory diseases. She aims to help strengthen Indonesia’s scientific capacity by bridging computational predictions with experimental and preclinical validation to support the discovery of safer and more effective therapeutic prototypes.

Dr. D. Figueredo received her B.A. degree (1995, Biochemistry) from Faculty of Biology, Havana University, Cuba, and both her MSc (1995, Biomedicine) and PhD (1999 Pharmaceutical Sciences) degree from National Center for Scientific Research in Havana, and most of the results were done in the Department of Toxicology at the Free University in Amsterdam. Postdoctoral training in Molecular Toxicology and pharmacology was completed at the Faculty of Pharmacy in Toronto, Canada. She has been referee of scientific journals related with pharmacology. Other previous academic appointments include lecturer in different international meeting. She has been the recipient of National Award of Pharmacology twice from the Cuban Pharmacology Society. She worked as Expert for the evaluation of preclinical platform in South Africa. (CSIR). She is the focal point to the World Health Organization network for regulatory cooperation of herbal medicines (IRCH). She is a membership committee of International Union of Pharmacology (IUPHAR). She is the secretary of Latin-American Network of Pharmacogenetic. She is currently the Vice president of Cuban Pharmacology Society. At present she works in the Cuba Regulatory Agency as senior researcher, she is in charge of the evaluation of safety and efficacy of traditional, integrative and complementary medicines for registering. Dr. Remirez research is described in over 60 published research reports.

Prof. Ritmaleni, a distinguished scholar and researcher at Curcumin Research Center (CRC), Faculty of Pharmacy, Gadjah Mada University, Indonesia, has significantly advanced the field of medicinal chemistry, particularly in the study of curcumin analogues with antioxidant, antitubercular, antidiabetic, anticancer and other activities. She obtained her PhD from the School of Chemistry, University of Bristol, United Kingdom in 2004 under the supervision of Prof. V. K. Aggarwal. Since then, she has been trained a synthetic chemist. Prof. Ritmaleni has dedicated her career to exploring innovative solutions for combating infectious diseases in Indonesia, such as tuberculosis, which remains a major global health challenge. Her groundbreaking work on synthesizing and characterizing curcumin analogues has led to the discovery of several promising candidates with potent biological activities including antioxidant and antitubercular properties. This research not only demonstrates her scientific expertise but also reflects her unwavering commitment to improving public health outcomes. Throughout her tenure at Faculty of Pharmacy, Gadjah Mada University, Prof. Ritmaleni has consistently demonstrated excellence in research, teaching, and mentorship. Her contributions have been recognized through numerous publications and her success in securing competitive research grants. Furthermore, she has been instrumental in fostering a collaborative research environment, bringing together interdisciplinary teams to address complex scientific problems.

Dr. Fadi G. Saqallah is an Assistant Professor at the Faculty of Pharmacy, Al-Zaytoonah University of Jordan, where he teaches Medicinal Chemistry, Drug Design, and Phytochemistry. He also serves as the Head of the Advisory Board for the Pharmacy Students’ Research Club (PSRC), actively supervising undergraduate research projects and guiding students in scientific writing, conferences, and competitions to strengthen their research and analytical skills. Dr. Saqallah earned his Ph.D. in Pharmaceutical Chemistry from Universiti Sains Malaysia, where his research focused on the design and synthesis of novel dengue virus protease inhibitors, integrating computational drug discovery with organic synthesis and in vitro assays. In addition to his academic career, he has professional experience as a Senior Pharmacist, contributing to patient care, pharmacy management, and clinical supervision. His research interests span antiplatelet, anti-atherosclerotic, and anti-hyperlipidemic agents, as well as antineoplastic and antiviral drug discovery.

Hello, I am Dr Sayantan Shankar Roy, MD, currently pursuing my DM (Doctorate of Medicine) at the All India Institute of Medical Sciences, Bhubaneswar, India. I am actively involved in research and teaching undergraduate MBBS and BSc nursing students as well as postgraduate pharmacology students. My area of interests are Clinical Pharmacology, Pharmacometrics including Mechanistic modeling approaches like PBPK, PK/PD and QSP approaches, and Pharmacovigilance. Currently I am venturing into Machine Learning for developing prediction models using clinical data from our esteemed teaching hospital. In the future, I would like to work in the Pharmaceutical industry applying my skills in Mechanistic modeling approaches to aid in regulatory submissions and approvals.

Dr. Fadi G. Saqallah is an Assistant Professor at the Faculty of Pharmacy, Al-Zaytoonah University of Jordan, where he teaches Medicinal Chemistry, Drug Design, and Phytochemistry. He also serves as the Head of the Advisory Board for the Pharmacy Students’ Research Club (PSRC), actively supervising undergraduate research projects and guiding students in scientific writing, conferences, and competitions to strengthen their research and analytical skills. Dr. Saqallah earned his Ph.D. in Pharmaceutical Chemistry from Universiti Sains Malaysia, where his research focused on the design and synthesis of novel dengue virus protease inhibitors, integrating computational drug discovery with organic synthesis and in vitro assays. In addition to his academic career, he has professional experience as a Senior Pharmacist, contributing to patient care, pharmacy management, and clinical supervision. His research interests span antiplatelet, anti-atherosclerotic, and anti-hyperlipidemic agents, as well as antineoplastic and antiviral drug discovery.

Yuka Sasaki is a lecturer at Osaka Dental University, where she investigates the biological roles of poly(ADP-ribose) metabolism in cell differentiation and disease. At WCP 2026, she will present her recent findings on the effects of the PARG inhibitor PDD00017273 on osteoclast differentiation.

Roland Seifert obtained his PhD in pharmacology with Prof. Günter Schultz in Berlin (1992) and was a postdoc with Prof. Brian Kobilka (Stanford) from 1995-1998. From 1998-2004 he was Associate Professor at the University of Kansas. From 2004-2008 he chaired the Pharmacology Department at the University of Regensburg (Germany). Since 2008 he is the Director of the Institute of Pharmacology of the Hannover Medical School (Germany). Seifert works on cyclic nucleotide-mediated signal transduction and more general aspects of pharmacology including teaching, history and pharmacoeconomics. Seifert is the author of textbooks and serves as the Chairman of the German Pharmacological Society.

Dr. Gautam Sethi is a tenured Associate Professor in the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore. His research focuses on defining the mechanisms by which carcinogens and inflammatory stimuli activate oncogenic transcription factors, and on identifying novel inhibitors with therapeutic potential in cancer. Over the past several years, his work has resulted in more than 500 publications in high–impact, peer-reviewed journals. He serves on the editorial boards of leading international journals including Antioxidants & Redox Signaling, Military Medical Research, Phytomedicine, Genes and Diseases, International Journal of Cancer, Cells, Journal of Functional Foods, etc. Dr. Sethi has been recognized as a Highly Cited Researcher (Clarivate, 2020–2021), included in Stanford University’s World’s Top 2% Scientists list (2019–2025), and is ranked among the top 0.05% of scholars globally by ScholarGPS (2023–2025).

Dr. Gautam Sethi is a tenured Associate Professor in the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore. His research focuses on defining the mechanisms by which carcinogens and inflammatory stimuli activate oncogenic transcription factors, and on identifying novel inhibitors with therapeutic potential in cancer. Over the past several years, his work has resulted in more than 500 publications in high–impact, peer-reviewed journals. He serves on the editorial boards of leading international journals including Antioxidants & Redox Signaling, Military Medical Research, Phytomedicine, Genes and Diseases, International Journal of Cancer, Cells, Journal of Functional Foods, etc. Dr. Sethi has been recognized as a Highly Cited Researcher (Clarivate, 2020–2021), included in Stanford University’s World’s Top 2% Scientists list (2019–2025), and is ranked among the top 0.05% of scholars globally by ScholarGPS (2023–2025).

Dr. Sai Seto is a Lecturer in the School of Biomedical Sciences at UWA. He has a sustained interest in drug discovery and pharmacology research, aiming to identify new treatments for complex human diseases. Sai has received research support from various funding bodies, such as the NHMRC, the National Heart Foundation (NHF) of Australia, the University Grants Committee of the Hong Kong Government, and the Innovation and Technology Commission of the Hong Kong Government. He received the Exchange and Collaboration Award from the NHF for his work on sclerostin and abdominal aortic aneurysm, as well as a Bronze Medal at the 49th International Exhibition of Inventions. His current research focuses on the roles of sclerostin in vascular diseases and muscle disorders, as well as the use of herbal medicine to manage women’s health issues (e.g., mastitis and postmenopausal symptoms).

Dr. Elora Sharmin is an Associate Professor and Acting Chairman of the Department of Pharmacology at Bangladesh Medical University. She is a clinical pharmacologist with over 15 years of experience in pharmacovigilance, vaccine safety, toxicology, and clinical research capacity development. Dr. Sharmin established one of the first institutional pharmacovigilance centers in Bangladesh and has led multiple nationally funded research projects. She has received international training in poisoning management, regulatory science, and clinical trials, and is actively engaged in strengthening clinical trial infrastructure and translational research at her institution. Her work focuses on improving medicine safety, enhancing vaccine oversight systems, and building sustainable research capacity in low- and middle-income countries.

Chih-Jie Shen’s research expertise spans lipid metabolism, cell signaling, cancer metastasis, and epigenetics. He is particularly focused on elucidating the role of lipid metabolic dysregulation in the tumor microenvironment and its impact on immune suppression. His recent work investigates how lipid accumulation and receptors, such as CD36, facilitate drug resistance and metastasis in colorectal cancer via extracellular vesicles. Additionally, he explores the role of PAF and LPCAT2 in glioblastoma, specifically their mechanisms in suppressing gamma/delta T cell cytotoxicity and driving immune evasion. He is dedicated to developing novel therapeutic strategies targeting these metabolic nodes.

Dr Yun Shi is an ARC DECRA Fellow and an NHMRC Investigator (Emerging Leadership 1) with multiple high-impact publications in journals such as Science and Molecular Cell. He integrates biophysical, biochemical, structural, and computational approaches to investigate protein-ligand interactions. Dr Shi obtained his PhD in Chemistry from Simon Fraser University (2015) before his postdoc at Griffith University. With a Griffith University Postdoctoral Fellowship (2016), he established a fragment-based drug discovery platform using nuclear magnetic resonance (NMR) spectroscopy as the primary technique. His current research focuses on fragment-based drug design, molecular function of nicotinamide adenine dinucleotide (NAD+) metabolites, and small-molecule modulation of enzymes in NAD+ metabolism that are promising therapeutic targets against neurodegeneration and other diseases.

Chih-Vhin Shih is a pharmacist who became a pioneer in the field of sepsis research during his master’s and PhD programs. After completing his PhD, he established an animal model for heat stroke to test new potential drugs, aligning with the unique developments at his institution. He further expanded his research interests into platelet molecular pharmacology and related experimental work. As a result, his research findings not only focus on new pathogenic mechanisms and the therapeutic effects of potential drugs for sepsis and heat stroke, but also explore the molecular mechanisms underlying changes in platelet function and the role of platelets in promoting wound healing and tissue regeneration. His work provides valuable insights for the future design and clinical application of treatments for sepsis and heat stroke, as well as therapies derived from platelet products.

Dr. Ming-Yi Shen is a cardiovascular researcher and faculty member in the Graduate Institute of Biomedical Sciences at China Medical University in Taichung, Taiwan. His work focuses on the molecular mechanisms by which modified lipoproteins—particularly electronegative LDL and ApoC3-rich LDL—drive endothelial dysfunction, platelet hyperactivation, and ischemic stroke. Dr. Shen’s research integrates clinical lipid profiling with mechanistic studies in cellular and animal models to uncover how lipoprotein quality, beyond traditional cholesterol levels, contributes to thrombotic and vascular injury. His recent work highlights the roles of NOX2-mediated oxidative stress, autophagy–vWF signaling, and natural antioxidant compounds as potential therapeutic targets in cardiovascular and cerebrovascular disease. He has published extensively in the fields of thrombosis, atherosclerosis, and vascular biology, and actively collaborates on National Science and Technology Council, Taiwan (NTSC)-funded research programs. Dr. Shen is also deeply engaged in mentoring medical and graduate students, fostering interdisciplinary approaches to translational cardiovascular research.

Eti Nurwening Sholikhah is a Professor of Pharmacology and Therapy at the Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada (UGM), Yogyakarta, Indonesia. She earned her Medical Doctor degree from UGM in 1993, followed by a Master’s degree and Doctorate in Pharmacology from the same institution. She also holds a Master’s degree in Medical Education and is certified as a Primary Care Family Medicine Specialist. Her academic and research interests encompass pharmacology, toxicology, drug development from natural products, antimalarial and anticancer agents, and herbal medicines.

Mr. Kyoung-jin Kang is a graduate student in the Department of Pharmacology at Yonsei University College of Medicine, South Korea. His current research focuses on the validation of Autophagy-targeting chimeras (AUTACs) designed to selectively degrade pathogenic α-synuclein aggregates. He aims to evaluate the efficacy of novel AUTAC candidates in PFF-induced cellular models of Parkinson's disease and to identify potential lead compounds for future in vivo studies. He is also interested in elucidating the specific autophagic pathways through which these AUTACs clear aggregates.

Michael Spedding is recognised as one of the 150 most cited researchers in France (2013–2020, Clarivate, all disciplines). He has authored over 230 scientific papers, holds more than 20 patents, and has advanced approximately 40 compounds into formal preclinical research, 11 into clinical development, and one to market, contributing to three additional marketed drugs. With 35 years of experience on research review committees for Merrell Dow, Syntex, and Servier, he has extensive insight into the processes by which drugs succeed or fail. He served as Chairman of NC-IUPHAR, expanding the committee from 15 to 90 subcommittees, involving 700 scientists and producing 100 publications, and has been Secretary-General of IUPHAR, linked to WHO, since 2014. Dr Spedding was elected to the French Academy of Pharmacy in 2001, became a Fellow of the British Pharmacological Society in 2005, and was awarded Honorary Fellowship in 2017. He has also overseen the construction of two research centres: SRIMC in Budapest and Croissy, Servier.

Dr. Surender Singh has been faculty of pharmacology for more than thirty-five years of which seventeen years in All India Institute of Medical Sciences, New Delhi and presently working as Professor in Department of Pharmacology. He has to his credit ten books, scientific series and over 140 scientific papers in indexed journals with total citation of 9255 with h-Index 46, i10 -index-124 and completed over 40 Research projects funded by different research funding Government agencies e.g., JSPS, UCL, ICMR, DST, DBT, UGC, AIIMS, AYUSH. He has guided over 75 MSc/MPharm/MDS/MD/DM/PhD and PDF theses research work. He is recipient of Gold Medal, M.Pharm. (Pharmacology) DIPSAR (University of Delhi), 1989, JSPS-Asia Africa Science Platform Programme, Japan Best Paper Award, 2011, All India Institute of Medical Sciences (AIIMS) Excellence Research Award, 2016, Dr. B. Mukherjee Prize, Indian Pharmacological Society, 2016, Dr. DN Prasad Memorial Oration Award, ICMR for Biomedical Research, 2017 and prestigious National ICMR award for biomedical research for his research contribution in the field of Pharmacotherapy of inflammatory disorders. Dr. Singh have been listed in the “World’s top 2% Scientists” list published by the Stanford University, USA. He is a Distinguished Visiting Professor, UCSI University, Kuala Lumpur, Malaysia. He has made significant contributions in the field of pharmacotherapy of inflammatory disorders using cytokine profiling and respective characterization for establishing the disease modifying agent in the treatment of rheumatoid arthritis. He is a member of several academic, professional and scientific advisory committees of Government of India. He is a Fellow of National Academy of Medical Sciences (FAMS), India, Fellow of Royal Society of Chemistry (FRSC), United Kingdom, Fellow of International Medical Science Academy, India (FIMSA) and Fellow of Institution of Chemists (FIC), India.

Professor Vetriselvan Subramaniyan, PhD, FMSA, FIABMS, is a Professor of Pharmacology at the Faculty of Medical and Life Sciences, Sunway University, Malaysia. He has over 15 years of teaching, research, and academic leadership experience across leading institutions, including Monash University Malaysia, Arba Minch University (Ethiopia), and MAHSA University (Malaysia). He has authored over 400 publications with a cumulative impact factor exceeding 1800, filed eight international patents, and contributed to six book chapters. His research excellence is recognized through multiple grants, including FRGS funding from Malaysia’s Ministry of Higher Education, and he is ranked among the Top 2% of Scientists globally by Stanford University. Professor Vetriselvan has served in senior academic leadership roles, supervised numerous postgraduate researchers, and delivered keynote lectures at over 30 international conferences. His research focuses on drug development and translational pharmacology.

Dr Jessica Stolp is a senior scientist within the biology team at Syntara, where she investigates targets and inhibitors of inflammation and fibrosis. With over a decade of experience in research, both academic and industry, Jessica is looking forward to presenting her teams work investigating Syntara’s lead candidate Amsulostat impacting the function of growth factor receptors.

Dr. dr. Rul Afiyah Syarif, M.Kes., is an associate professor in Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Indonesia. Her expertise includes ethnopharmacology (herbal medicine), reproductive pharmacology, and medical pharmacy. In addition to teaching students, she also conducts research focused on herbal medicine, both in vitro and in vivo. She has experience in primary cell culture such as isolating and culturing rat luteal cells and porcine granulosa cells. Several cell lines including Plasmodium falciparum are also the subject of her herbal research. The in vivo research focus on galactagogues, fertility regulators, immune booster, antidiabetics, and reproductive system. More detailed scientific work can be seen on the ORCID page https://orcid.org/0000-0001-8114-9322 and SCOPUS ID 57204936298.

Vivian Soetikno, MD, PhD is a Clinical Pharmacologist and Head of the Department of Pharmacology and Therapeutics at the Faculty of Medicine, Universitas Indonesia. Her research focuses on renal pharmacology and herbal medicine.

Siti Syarifah is an associate professor in Dept.of Pharmacology & Therapeutics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia. Siti graduated from Faculty of Medicine, Universitas Sumatera Utara with Philosophy Doctor in Medicine in 2024. Siti specializes in pharmacogenetic and herbal medicine in breast cancer patients. With over ten years of experience, she has been published in Molecules, Breast Cancer: Targets and Therapy and numerous science and medicine journals. She earn university and national research grants since 2017. Siti currently enjoys being a reviewer in reputable journals including Frontiers in Medicine, Frontiers in Immunology and national pharmacology journals.

Kosei Takeuchi is a master student in the Section of Neuromedical Science, Institute of Natural Medicine, University of Toyama. His research focuses on neuron-derived secreted proteins that may play an important role in neural circuit regeneration, with a particular focus on axonal regeneration.

Fuka Tamura is a fifth-year medical student at Sapporo Medical University, affiliated with the Department of Pharmacology. She is currently pursuing her medical studies with a focus on pharmacological research.

Dr. Zhenghai Tang is an Assistant Professor at the Faculty of Health Sciences, University of Macau. He obtained his Ph.D. from the university of Macau in 2017 and subsequently conducted postdoctoral research at the Montreal Clinical Research Institute until 2024. His major research interests focus on the identification of novel immune checkpoints in immune cells for cancer immunotherapy and the development of first-in-class therapeutic antibodies against cancer. Dr. Tang has published work as first or corresponding author in leading journals such as Nature Immunology, Science Immunology, Nature Nanotechnology, and Cell Reports. He has received research support from the Type B Young Scientists Fund of the National Natural Science Foundation of China, the Macau FDCT, and the University of Macau.

Julyan Tan is a PhD candidate in the School of Biomedical Sciences at the University of Western Australia, and based at Harry Perkins Institute of Medical Research. His research focus is on the detection of novel receptor heteromers formed between G protein-coupled receptors and scavenger receptors, which are pertinent in pro-inflammatory signalling. Characterising the pharmacology of these receptor heteromers - ligand-binding, signalling and intracellular trafficking - may then contribute to a better understanding of inflammatory disease biology.

Prof. Liqin Tang is a leading researcher at the First Affiliated Hospital of USTC, whose research endeavors have yielded groundbreaking contributions to diabetes and its complications. She has dedicated substantial efforts to exploring the pathogenesis of diabetes, unraveling intricate mechanisms, and identifying promising drug treatment targets. Beyond diabetes research, professor Liqin Tang is dedicated to pioneering innovative strategies for cancer diagnosis and therapy, ranging from nanomaterial-based diagnostic probes to targeted drug delivery systems.

Feng (Ruby) completed her BPharmSc (Hons) at Monash Institute of Pharmaceutical Sciences. Afterwards, she worked as a research assistant before starting her PhD in 2024. Her project is on understanding the structure and function of the neuropeptide S receptor 1.

Assistant Professor Anusorn Thampithak, Ph.D. serves in the Division of Pharmacology and Biopharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Burapha University, Thailand. He earned his Ph.D. in Pharmacology from Mahidol University and his Doctor of Pharmacy (Pharm.D.) from Burapha University. His research focuses on neuropharmacology, with particular emphasis on the molecular mechanisms underlying neuroinflammation and neurodegenerative disorders, including microglial activation and intracellular signaling pathways. He also investigates the pharmacological activities of bioactive compounds derived from medicinal plants, especially their antioxidant, anti-inflammatory, and neuroprotective properties. He has published extensively in peer-reviewed international journals and has led and collaborated on multidisciplinary research projects in pharmacology and natural products. In addition to his research, he is actively engaged in pharmacy education, curriculum development, and mentoring undergraduate and graduate students in experimental pharmacology and translational research.

Dr Bui San Thai is a Postdoctoral Research Fellow in the Cardiac GPCR Biology Laboratory under the supervision of A/Prof Lauren May at Monash University (Parkville campus), specialising in G protein-coupled receptor (GPCR) pharmacology and cardiovascular (patho)physiology. She obtained her Bachelor of Pharmaceutical Science (Honours) in 2016 and her PhD in 2021. Her doctoral research focused on adenosine receptors as therapeutic targets for myocardial infarction and heart failure, with particular emphasis on the impact of ageing and diabetes. In her current role, she investigates the adenosine A1 receptor using human-induced pluripotent stem cell models to explore its therapeutic potential in cardiovascular disease and epilepsy. Beyond her research, she serves as a Networking and Mentoring Pillar Lead for Her Research Matters and a secretary for ASCEPT Drug Discovery SIG in 2026.

Diana L. Torres-Chacón, Master of Science in Experimental Biology, is a doctoral researcher in the Pharmacology Laboratory at Autonomous Metropolitan University, Iztapalapa, México, where she specializes in the study of natural products to combat chronic-degenerative diseases such as diabetes, obesity, cancer and inflammation. Her investigation focuses on mechanism of action at molecular level. She has experience extends beyond academia, as she has also actively participated in product development projects with general applications, including nutraceuticals, cosmetics, and phytomedicines. Her participation in WCP 2026 highlights her multidisciplinary approach that combines basic science with innovation.

Diana L. Torres-Chacón, Master of Science in Experimental Biology, is a doctoral researcher in the Pharmacology Laboratory at Autonomous Metropolitan University, Iztapalapa, México, where she specializes in the study of natural products to combat chronic-degenerative diseases such as diabetes, obesity, cancer and inflammation. Her investigation focuses on mechanism of action at molecular level. She has experience extends beyond academia, as she has also actively participated in product development projects with general applications, including nutraceuticals, cosmetics, and phytomedicines. Her participation in WCP 2026 highlights her multidisciplinary approach that combines basic science with innovation.

Danyelle Townsend attended the University of Virginia Medical School, focusing on Cancer Biology and Drug Metabolism. She is currently the acting Department Co-Chair and Professor of Drug Discovery and Biomedical Sciences at the Medical University of South Carolina and Director of the Redox Bioenergetics and Functional Metabolomics Core. Her laboratory combines proteomics and analytical biochemistry to identify molecular targets of oxidative and nitrosative stress to determine how redox signaling impacts cellular response. Dr. Townsend's research on the redox proteome and associated pathways created a platform for drug discovery and redox biomarker development that has led to multiple clinical trials.

Prof. Chinenye Jane Ugwah-Oguejiofor is a Professor of Pharmacology and Toxicology at Usmanu Danfodiyo University, Sokoto (UDUS), Nigeria. She holds a B. Pharm and a PhD from the University of Nigeria, Nsukka (UNN), and an M.Sc. in Pharmacology from UDUS. Her research focuses on natural products for the prevention and management of diseases, particularly those affecting women. She also leads research groups exploring natural product-based interventions for Alzheimer’s disease and polycystic ovarian syndrome. Prof. Ugwah-Oguejiofor has supervised numerous M.Sc. and PhD students and has presented over fifty scientific papers at national and international meetings. She has published more than seventy peer-reviewed articles, secured multiple institutional and national research grants, and maintains active international collaborations, including with the Norxin Medical Research Cooperation Centre, China. She has also received several competitive travel grants. She serves as an Editor with BMC Complementary Medicine and Therapies and is a member of the UDUS Human and Animal Ethics Committee. She belongs to PSN, NISPET, ASPET, and WASP and is the Immediate Past Chairperson of the Association of Lady Pharmacists, Sokoto Chapter.

I am currently an Instructor in the Department of Biochemistry and Molecular Biology at the University of Arkansas for Medical Sciences. I hold dual Ph.D. degrees in Chemistry and Health Sciences, along with a Graduate Certificate in Regulatory Sciences. I serve as Chair of the Division for Drug Discovery and Development and Co-Chair of the Partnerships Committee at the American Society for Pharmacology and Experimental Therapeutics. My research focuses on cancer pharmacology, particularly natural-product-derived compounds and their analogs, with an emphasis on immunostimulatory mechanisms in breast cancer and melanoma. I am also passionate about patent law and its role in advancing scientific innovation.

Dr. Gyan Vardhan is a pharmacologist and clinical researcher currently serving as Senior Resident in the Department of Pharmacology at AIIMS Rishikesh, with a Ph.D. in Pharmacology and extensive experience in experimental and clinical research. His work spans clinical trials, bioanalytical and chiral chromatographic method development, pharmacogenetics, and oncology-related translational research, with over 25 peer-reviewed publications. He has received competitive research funding from the Indian Council of Medical Research (ICMR), including an extramural grant and Senior Research Fellowship, and has been honored with the Best Researcher Award from AIIMS in recognition of his significant scientific contributions and academic excellence .

Dr Elizabeth Vecchio is a National Health and Medical Research Council (NHMRC) Early Career Fellow within the Hypertension Research Laboratory at the Victorian Heart Institute, Monash University. Her research expertise lies in G protein-coupled receptor (GPCR) molecular pharmacology. Prior to completing her PhD at the Monash Institute of Pharmaceutical Sciences in 2017, Dr Vecchio worked as a clinical pharmacist. Her doctoral research characterised the pharmacology of the adenosine A₂B receptor, with a particular focus on constitutive activity and signalling bias. Her current research investigates the mechanisms by which gut microbiome–derived metabolites modulate blood pressure through activation of short-chain fatty acid and pH-sensing GPCRs.

Yutong Chen is a M.Sc. student in Chinese Medicinal Science at the Institute of Chinese Medical Sciences, University of Macau. She obtained a B.Sc. in Pharmacy from Southern Medical University, China. During her M.Sc. study, her research is focused on studying the effects of Chinese medicine in Type 2 Diabetes and Ulcerative colitis.

Dr. Kai Wang obtained his Ph.D. in Clinical Pharmacy from China Pharmaceutical University and now serves as an assistant researcher at Anhui Provincial Hospital. His research is dedicated to addressing frontier scientific questions in metabolism, immunomodulation, and targeted drug discovery, aiming to establish a scientific foundation for novel therapeutic strategies.

Prof. Dr. apt. Mae Sri Hartati Wahyuningsih, M.Si. is a senior lecturer and researcher at the Center for Herbal Medicine and the Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Indonesia. With more than 15 years of expertise in natural product research, her work focuses on bioassay-guided isolation approach for drug discovery from medicinal plants, particularly for antidiabetic therapy. Her current research integrates bioassay-guided fractionation, in vitro pharmacological evaluation, and in silico analysis to identify and characterize bioactive compounds. At this conference, she will present her latest findings entitled “Bioassay-Guided Fractionation of Clinacanthus nutans: An In Vitro and In Silico Approach"

Dr. WANG Zhao is currently Senior Professor in the School of Pharmaceutical Sciences at Tsinghua University. He obtained his B.S. in Clinical Medicine with honors from Henan College of Chinese Medicine in 1982, and a Master Degree in Basic Medicine from Beijing University of Chinese Medicine in 1987. Then he went to Japan and obtained his Master Degree in Biopharmaceuticals from National Okayama University (Japan) in 1993, and his Pharm.D. in Pharmaceutical Sciences from the same University in 1996. Dr. WANG has worked on studying of aging and aging related diseases as well as their biological mechanisms, with a focus on neuropharmacology and metabolic pharmacology, especially the pharmacology related with brain aging, bone aging and degenerative diseases such as AD and osteoporosis.

Dr. Wei Wei, MD, Ph.D, is Shuyun Xu Chair Professor at Anhui Medical University (AMU), where he has served since 1986. He is the Founding Director of the Key Laboratory of Anti-inflammatory and Immune Medicine (AMU), Ministry of Education of China. Dr. Wei currently serves as President of the Chinese Pharmacological Society (13th Council) and as a member of the Medical and Clinical Pharmacology Committee of IUPHAR. He is Editor-in-Chief of the Chinese Pharmacological Bulletin and an Editorial Board Member of Acta Pharmacologica Sinica. His research focuses on anti-inflammatory immunopharmacology and clinical pharmacology. He has led over 10 major projects, including key grants from NSFC. Dr. Wei contributed significantly to the development of total glucosides of paeony (TGP) for rheumatoid arthritis, which has generated substantial socioeconomic benefits since its market approval. He is the editor in chief of Methodology of Pharmacological Experiments (4th Ed.) and other major textbooks.

Professor Tri Widyawati, MD, M.Si, PhD, is a pharmacologist in the Department of Pharmacology and Therapeutics, Faculty of Medicine, University of North Sumatra (USU), Medan, Indonesia. She earned her MD (2001) and Master’s degree in Pharmacy (2007) from USU and completed a PhD in Pharmacology at Universiti Sains Malaysia (2016). She teaches pharmacology across Medicine, Dentistry, Nursing, Tropical Medicine, and Biomedical Science, and serves as a guest lecturer in allied health and specialist programs. Her research focuses on natural product pharmacology, metabolic disease, and translational therapeutics, with over 80 publications including work on Indonesian botanicals, malnutrition, neuroprotection, and metabolic control. She has authored textbooks and monographs, received multiple awards and grants, and holds patents and intellectual property in botanical formulations and drug delivery technologies. Prof. Widyawati is actively involved in mentoring, innovation, pharmacology education, and community-engaged learning, with current interests in antibiotic stewardship, rational self-medication, and evidence-based herbal medicine.

Jiangchuan Xie, Master of Pharmacy, graduated from Chongqing Medical University. With nearly a decade of clinical experience, I specialize in clinical drug application, pharmacovigilance, clinical trial management, as well as novel drug dosage forms and technologies.

Dr. Xin Feng Wu holds a doctoral degree in Pharmacology from Capital Medical University. Currently employed at Xuanwu Hospital, affiliated with Capital Medical University. Professional work focuses on the development of drug targets and the early pharmacological evaluation of novel compounds.

Dr. Ewura Seidu Yahaya is a Lecturer of Pharmacology at the School of Medical Sciences, University of Cape Coast, Ghana. He holds a PhD in Pharmacology from the University of Pretoria, South Africa. His research-focused areas include molecular and cellular mechanisms of wound healing, antimicrobial drug development, drug interaction profiling and natural product pharmacology. Dr. Yahaya has several peer-reviewed publications in reputable scientific journals, and has presented at numerous national and international conferences. Dr. Yahaya is currently exploring the potential of structurally modified antibiotics as novel treatments for infection, as well as the impact of drug interactions on antimicrobial resistance. He is also a facilitator of his school’s community outreach activities which provides health education and services to mostly rural and poorly resourced communities across Central and Eastern Ghana. He is passionate about improving human health and quality of life through scientific research and knowledge impartation.

Rong Xu is a professor and doctoral supervisor in the Department of Pharmacology, School of Basic Medical Sciences, Tongji Medical College, Huazhong University of Science and Technology. Her research focuses on tumor pharmacology and clinical pharmacology. She has led projects funded by the National Natural Science Foundation of China, the Hubei Provincial Natural Science Foundation Outstanding Youth Fund, and others. Her representative papers have been published as corresponding author or first author in journals such as Nat Biotechnol, ACS Nano, Small, J Exp Clin Cancer Res, and J Adv Res. She has also contributed to the writing of textbooks, including "Clinical Pharmacology" and "New Clinical Drug Therapy.

Guo Hongwei, Ph.D., Professor, Doctoral Supervisor, and Director of the Science and Technology Department at Guangxi Medical University. He has been selected as a National Young Qihuang Scholar and a Guangxi Bagui Scholar. He has been a visiting scholar at the University of Michigan, USA, and the University of Melbourne, Australia. he serves as the Deputy Director of the Fermented Traditional Chinese Medicine Professional Committee of the CACM, and a Standing Committee Member of the Clinical Chinese Materia Medica Branch of the CPA. He also holds concurrent positions as the Director of the "Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica" and the Executive Deputy Director of the "Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation." He has led four projects funded by the NSFC, and as a corresponding author, he has published over 50 SCI-indexed papers. He holds 12 authorized national invention patents, with one project having undergone technology transfer. As the principal investigator, he has won a second prize of Guangxi Natural Science Award. He currently serves as a youth editorial board member for SCI Q1 journals including Chin Med, Chin J Nat Med, and Chin Herb Med.

Dr. Siming Yuan obtained Ph.D. in Chemical Biology from University of Science and Technology of China. Currently serving as an associate professor at the First Affiliated Hospital of the University of Science and Technology of China, his research endeavors focus on the rational design of novel metal compounds with enhanced anticancer properties, exploring innovative targeted delivery strategies to improve drug efficacy and reduce side effects, and elucidating the underlying molecular mechanisms of these therapeutics.

Xiangqi Zhang Ph.D from Shanghai Jiaotong University Serve as a junior Pharmacists in Department of Pharmacy, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Frankie is a 3rd year PhD student who is undertaking his PhD in the Integrated Neurogenic Mechanisms Lab (Monash University), where he is studying the spatio-temporal signalling profile of the Transient Receptor Potential Vanilloid 4 (TRPV4) ion channel under the supervision of A/Profs Nicholas Veldhuis, Daniel Poole, Shireen Lamande, and Dr Chris Horne. Leveraging super-resolution imaging and newly developed spatio-temporal tools, he hopes to uncover novel signalling paradigms of the TRPV4 channel.

SIQI ZHANG is a final-year PhD candidate in the Department of Natural Product Drug Development at the Korea Institute of Science and Technology. Her research focuses on the discovery and characterization of bioactive natural products from animal, plant, and microbial sources as functional materials and therapeutic leads, with an emphasis on translational development and bio-industry applications, including the identification of drug-like small molecules and biologics for chronic metabolic diseases, inflammation, and depression & neurological disorders. Her work integrates in vitro and in vivo disease models with molecular pharmacology and multi-omics approaches to elucidate mechanisms of action and support target-driven therapeutic development. She is committed to advancing natural product–inspired therapeutics with clinical and industrial relevance.

Duanfang Zhou is a medical doctor specializing in anti-tumor pharmacology at the Women and Children’s Hospital of Chongqing Medical University. Her research focuses on identifying novel therapeutic targets and elucidating their mechanisms in breast cancer development. She is also focus on the discovery and development of new anti-cancer agents, aiming to advance personalized and precision cancer therapy through translational research.

Weiying Zhou, Ph.D., is a full professor and director of Department of Phamacology at College of Pharmacy in Chongqing Medical University (CQMU). She is a vice chairman of the Chemotherapy Pharmacology Professional Committee of the Chinese Pharmacological Society. Her research interests focus on pharmacology of anti-cancer drugs and anti-metabolic disorder drugs. Her research is also on the basic biological aspects of breast cancer and prostate cancer, such as the mechanisms of invasion and metastasis and chemotherapy resistance. She has published over 30 peer-reviewed articles as the first/corresponding author in the scientific journals including Cancer Cell, British Journal of Pharmacology, Phytomedicine, Journal of Translational Medicine, Neoplasia, npj Breast Cancer, Biochemical Pharmacology, EUR J PHARMACO, and Journal of Drug Targeting.

Associate Professor, State Key Laboratory of Mechanism and Quality of Chinese Medicine, Macau University of Science and Technology. Dr. Zhu obtained his PhD degree in pharmacology from Peking Union Medical College in 2008, and then took postdoctoral training in Nanyang Technological University and the Chinese University of Hong Kong. In 2014, he joined Macau University of Science and Technology. His current research interests include drug discovery targeting protein degradation and design of novel drug delivery systems for natural products, especially focusing on the synergistic pharmacological activities of the nanocarriers. In 2017, he got the CNPHARS-Servier Prize for Young Investigators in Pharmacology in China.

Sulli Zhong (Yuwen Zhong) is a Master’s candidate in Pharmacy at the School of Pharmaceutical Science, Shanghai Jiao Tong University (2023-2026), with a B.Sc. in Traditional Chinese Medicine from Shanghai University of Traditional Chinese Medicine (2019-2023). Her research focuses on tumor immunotherapy, natural product pharmacology, and advanced drug delivery systems. Key research includes developing novel anti-IL-33 antibodies for hepatocellular carcinoma (HCC) treatment, investigating natural compounds (e.g., berberine, dehydrocostus lactone) in suppressing HCC via signaling pathway regulation, and constructing microneedle-based transdermal delivery systems for alopecia areata therapy. She has published 4 SCI papers (JCR Q1, IF up to 14.1) in journals including Advanced Science and Chemical Engineering Journal, with 4 additional manuscripts under review/revision (JCR Q1). Proficient in core experimental techniques (molecular cloning, signal detection, tumor/lung disease model construction, protein purification) and academic tools, she has been awarded multiple scholarships for academic excellence. Her work aims to advance translational research in cancer immunotherapy and innovative drug development.

Yuanyuan ZHU Postdoctoral Fellow (2024.09 - Present) School of Basic Medical Sciences, Fudan University Ph.D., Pharmacology (2020.09 - 2024.06) Fudan University M.S., Immunology (2013.09 - 2016.06) Soochow University B.S., Biotechnology (2009.09 - 2013.06) Soochow University

I am a fourth-year student of the Bachelor of Pharmacy (Honours) at The University of Sydney, who is passionate about pharmacological innovation and individualized medication using technology and artificial intelligence for oncology, neuropharmacology, and pharmacogenomics.

Koh is from Hokkaido, the northernmost island of Japan. He works on the hypoxic response of cancers, as hypoxic conditions induce malignant phenotypes in cancer. In his poster, he will introduce how hypoxic conditions alter the chromatin structure of cancer cells. If you have time, please stop by!

Dr. Varsha Rathore completed her Ph.D. in 2025 at the College of Medicine, National Taiwan University. Her doctoral training was supported by the Taiwan International Graduate Program and fellowships from the National Science and Technology Council (NSTC), Taiwan. It involved interdisciplinary collaborations with Academia Sinica and National Tsing Hua University. Her research interests focus on cancer biology and pharmacology, particularly understanding how cancer cells adapt to stress and therapeutic challenges. Beyond research, Dr. Rathore enjoys practicing yoga and exploring new cultures through travel, which she finds inspiring for both personal growth and scientific creativity.

Beatrise Luīze Revina is a researcher and PhD student with a background in pharmacy at the faculty of Medicine and Life Sciences of University of Latvia, where she works in department of Neuromedicine and Neuroscience. Her research focuses on CNS biomarkers of neurodegenerative diseases and mitochondrial respiration. Her professional interests include health sciences and interdisciplinary approaches to research and practice.

Satoshi Shimizu is an Assistant Professor at the School of Pharmaceutical Sciences, University of Shizuoka. He received his Doctor of Philosophy in Pharmaceutical Sciences from the University of Shizuoka in March 2022. His research focuses on elucidating the mechanisms underlying sex differences in cardiovascular and renal tissues, with particular emphasis on membrane protein regulation and multi-omics approaches. Prior to his current position, he conducted postdoctoral research at Jikei University under the supervision of Professor Nagamori, where he further developed expertise in membrane transporter biology and cellular physiology. Through integrated biochemical and omics-based analyses, his work aims to clarify how sex hormones and sex chromosomes shape organ-specific molecular networks and contribute to functional diversity.

Baiba Svalbe is a Leading Researcher at the Latvian Institute of Organic Synthesis, Laboratory of Pharmaceutical Pharmacology, and holds a PhD in Pharmacy. Her research expertise includes the design and performance of in vivo mouse cancer models, pharmacokinetic and behavioural studies in rats and mice, analysis of spermatozoa quality in different mouse strains, and the breeding of genetically modified animal models. She has also contributed to the improvement of multicentre protocols for traumatic brain injury, with her current research focusing on novel biomaterials and drug testing using in vivo mouse cancer models.

Daniel Stránský, MD is a physician and PhD student at the Institute of Pharmacology, First Faculty of Medicine, Charles University, and the General University Hospital in Prague. His research focuses on inflammation and immunomodulation, with particular emphasis on the orexin and endocannabinoid systems and their therapeutic potential in inflammatory diseases. His doctoral training combines experimental and clinical pharmacology, including cell cultures, pharmacokinetic approaches, and in vivo animal models of inflammatory disease.

Dr. Uppugunduri holds a PhD Pharmacogenetics/Medical Pharmacology. He is currently working as an assistant professor in Department of Medical Oncology, JIPMER, Puducherry. He completed PhD at Department of Pharmacology, JIPMER, Puducherry in 2010 during which he received the Indo-Swiss Research Fellowship. Following completion of PhD, he continued to work in pharmacogenetics/omics at CANSEARCH Research platform of pediatric oncology and hematology of University of Geneva and headed the experimental research division until May 2024. He is a recognized Clinical Pharmacologist from Swiss Society of Clinical Pharmacology and Toxicology (SSCPT). His research is focused on pharmacogenetics and personalized medicine with particular contributions in elucidating drug responses, drug-drug interactions in relation to genetic variants. Dr. Uppugunduri has keen interest in utilizing in silico and in vitro models to understand the PK behavior as well as pharmacodynamic activity of several drugs.

Wu Yu is a current doctoral student in pharmacology at the School of Basic Medical Sciences and Forensic Medicine, West China University, Sichuan Province

Dr. Kodai Yajima is an Assistant Professor at the Faculty of Pharmacy, Keio University, Japan. He specializes in clinical pharmacology, with a particular focus on the immunogenicity of biopharmaceuticals. His current research utilizes AlphaFold3 to predict antigen-antibody drug interactions, aiming to enhance the development and safety of biologic therapies.

Dr. Yiwen Zhang focus on clinical pharmacology and pharmaceutical science. She serves in numerous leadership roles across national and regional academic organizations, including Young Board Member of the Chinese Anti-Cancer Association and Standing Committee Member of the Pharmacogenomics Committee of the Chinese Pharmacological Society. She also holds key positions such as Vice President of the Clinical Trial Branch of the Zhejiang Association of Translational Medicine, Deputy Director of the Precision Pharmacy Committee and the Pharmaceutical Toxicology Committee of the Zhejiang Pharmaceutical Association. Dr. Zhang has led 12 funded projects, including grants from the National Natural Science Foundation of China (General and Young Programs), the Zhejiang Provincial Key Research and Development Program, and the Zhejiang Provincial Natural Science Foundation. She has published 41 SCI-indexed papers such as Cancer Research, Advanced Science, Drug Resistance Updates, and Journal of Experimental & Clinical Cancer Research (JECCR).

Zhou Di, Ph.D., is a Pharmacist-in-Charge at the Phase I Clinical Trial Research Laboratory of The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital). He earned his Ph.D. in Pharmacology from Shandong University in 2020. His work integrates clinical practice with scientific research, focusing on clinical drug trials, clinical pharmacology, and nephrology pharmacology, with a particular emphasis on the pathogenesis of kidney diseases, especially diabetic nephropathy. Dr. Zhou has authored 7 SCI publications, including three as first author and one as corresponding author. His notable papers have appeared in journals such as Cell Death & Disease (159 citations) and Molecular Therapy Nucleic Acids. He currently serves as the Principal Investigator of a National Natural Science Foundation of China Youth Science Fund Project and has participated in several innovative drug clinical trials. Current professional roles include: Member, Drug Clinical Research and Evaluation Committee, Anhui Medical Doctor Association; Secretary, Quality Control Center for Phase I Clinical Trials of Drugs, Anhui Province.

Mikael O. W. Piha is a Finnish doctoral researcher and physician specialising in clinical pharmacology. Piha is a clinician-scientist with equal passion in the art and science of medicine, and he has remained a part-time general practitioner for several years. He is also the treasurer of the Finnish Society of Clinical Pharmacology. Piha’s doctoral thesis focuses on potential drug-drug interactions involving blood pressure-lowering drugs, exemplified by the present clinical trial investigating the effect of the angiotensin II receptor blocker losartan on the antibiotic cephalexin.

Puiu Olivian STOVICEK is a Habilitated Associate Professor at the Faculty of Nursing, Titu Maiorescu University of Bucharest, Romania, and an Adjunct Associate Professor at the Faculty of Psychology, University of Craiova. He is a senior physician in clinical pharmacology at the “Sf. Nectarie” Oncology Center in Craiova, where he serves as a subinvestigator in international phase I, II, and III clinical trials. He also holds certifications in palliative care and healthcare management. His main professional interests focus on integrating clinical pharmacology and psycho-oncology into a holistic approach to oncology and palliative care. An important line of his research examines the impact of oncological treatments on mental status, associated psychological symptoms, and quality of life. His academic work includes a significant number of books, book chapters, and research articles published nationally and internationally.

Subindra Kazi Thapa is a PhD candidate at the Centre for Medicine Use and Safety, Monash University. He holds a Bachelor's in Pharmaceutical Sciences and a Master's in Pharmacy. He has over five years of experience in the pharmaceutical industry, focusing on the formulation of various dosage forms. He is currently pursuing a PhD in pharmacometrics, investigating how ageing and polypharmacy affect frailty progression. His research develops pharmacokinetic and pharmacodynamic models to describe interactions between physiological changes, drug effects, and disease progression in older populations. His work aims to strengthen quantitative modelling to optimize the safe and effective use of medications in vulnerable populations.

Prof. Dr. Petra A. Thürmann, MD, is Director of the Philipp Klee-Institute of Clinical Pharmacology, Helios University Clinic Wuppertal, Germany. Since 2021 she is Vice-President of the University of Witten/Herdecke. After studies of Medicine at the Johann Wolfgang Goethe-University in Frankfurt/Main she received a board certified specialist’s degree in Clinical Pharmacology in 1992 and PhD (Habilitation) in 1997. In 1997 appointment at the HELIOS University Clinic in Wuppertal and 1998 at the University of Witten/Herdecke. Petra Thürmann was member of the Executive Committee of IUPHAR between 2004 and 2018. She is member of the Drug Commission of the German Medical Association, served from to 2011 until 2023 at the Advisory Council on the Assessment of Developments in the Health Care System (German Ministry of Health) and belongs since 2023 to the Expert Advisory Council “Health and Resilience” of the Federal Government of Germany. Her research interest is focused on geriatric pharmacotherapy (e.g. PRISCUS list), drug therapy safety as well as gender medicine.

Shinya UCHIDA, Ph.D. is Professor in the Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences at the University of Shizuoka. He completed his B.Sc., M.Sc., and Ph.D. in Pharmacy at the University of Shizuoka. After clinical experience as a pharmacist at Hamamatsu University School of Medicine Hospital and subsequent academic appointments, he joined the faculty at the University of Shizuoka and was appointed full Professor in 2021. Dr. Uchida’s research focuses on clinical pharmaceutical sciences, including clinical pharmacokinetics, clinical pharmacology, formulation science, and patient-centered medication evaluation. His work encompasses pharmacokinetic/pharmacodynamic analysis, drug-drug interactions, and formulation design to improve therapeutic outcomes and medication adherence. He has authored numerous peer-reviewed publications and contributes actively to advancing pharmacy practice and science.

Dr. Yune-Fang Ueng earned her Bachelor of Science in Pharmacy from Kaohsiung Medical College in Taiwan and completed her PhD in Biochemistry at the College of Medicine, National Taiwan University. She subsequently undertook postdoctoral training in the Department of Biochemistry and the Center in Molecular Toxicology at Vanderbilt University in Nashville, USA. Dr. Ueng’s research focuses on drug metabolism, herb–drug interactions, and cytochrome P450 enzymes. She has an extensive publication record, with recent work exploring CYP450 inactivation mechanisms, the impact of herbal medicines on drug-metabolising enzymes, and clinically relevant herb–drug interactions. Her studies have been published in leading journals including Biochemical Pharmacology, Phytomedicine, the Journal of Pharmacy and Pharmacology, and Toxicology and Applied Pharmacology.

Somin Woo is a master’s student at the Graduate School of Pharmacy, Kyungpook National University, and a member of the AI Drug Discovery Laboratory. Her research focuses on artificial intelligence–driven drug discovery, with particular interest in graph neural networks and hybrid machine learning models for predictive pharmacology. Her long-term goal is to translate AI methodologies into practical tools applicable to real-world drug development, thereby accelerating early-stage decision-making and improving development efficiency.

Ventura Simonovich, MD, is President of the Argentine Association of Experimental Pharmacology and Head of the Clinical Pharmacology Section at Hospital Italiano de Buenos Aires. He leads clinical and translational research programs focused on early-phase development, with particular expertise in first-in-human studies and the clinical development of novel drugs and health technologies. His work spans protocol design and execution, regulatory and operational readiness, and the integration of precision-medicine approaches to accelerate safe, high-quality innovation from bench to bedside.

Tan Thai is a 5th year student undertaking the Bachelor of Pharmacy and Management (Hons) at the University of Sydney. An avid pharmacy student with an interest in molecular modelling, drug discovery and rational drug design. During his 4th year, Tan volunteered under Professor Thomas Balle in characterisation of the α4α4 nicotinic pharmacophore, later expanding into his formal Honours project during 2026. He maintains an ongoing focus on the research and development of drugs for neurodegenerative, neuropsychiatric and neurodevelopmental disorders.

Yuxin Zhuang is a postdoctoral fellow at Macau University of Science and Technology. His research focuses on: (1) Immunometabolism; (2) Pathogenesis of inflammatory/autoimmune diseases; (3) Anti-inflammatory drug target identification and drug discovery; (4) Mechanisms of TCM ingredients regulating Th17 cell differentiation.

Dr Andy Kuo is Assistant Director at the Centre for Integrated Preclinical Drug Development (CIPDD), an ISO9001-accredited facility within the School of Biomedical Sciences at The University of Queensland. In this role, he leads and contributes to commercially and competitively funded translational preclinical research projects. He has extensive experience in in vitro efficacy screening, in vivo pharmacodynamics, pharmacokinetics, and exploratory toxicology. Dr Kuo has strong experience collaborating with academic and industry partners and serves as Chief Investigator on numerous contract R&D studies funded by SMEs and large pharmaceutical companies. Although much of his work involves IP-sensitive research, he maintains a strong publication record in drug discovery and translational science, with 36 peer-reviewed publications and two book chapters. He has also advised or co-advised six PhD students, six Research Master’s and Honours students, and supervised 16 Master of Pharmaceutical Industry Practice placements.

Syedah Neha Ashraf is a Senior Scientist in Hit Discovery at AstraZeneca's Discovery Sciences division in Cambridge, United Kingdom. She leads high-throughput screening (HTS) campaigns to identify chemical starting points for next-generation therapeutics. Since joining AstraZeneca in 2020, Neha has delivered multiple campaigns, including pioneering protein-protein interaction activator and disruptor screens. Neha holds a BSc (Hons) in Pharmacology and Translational Medical Science from Imperial College London and an MBA from Quantic School of Business and Technology. Her career spans drug discovery roles at GlaxoSmithKline and Sygnature Discovery, complemented by critical contributions to COVID-19 diagnostics as a Team Leader at UK National Lighthouse Laboratories during the pandemic. Neha combines technical expertise in various screening technologies and state-of-the-art assay automation with a commitment to advancing scientific excellence and inclusive practices in drug discovery.

Whitney Venturini is a pharmacist and PhD in Biomedical Sciences, and an academic at the Department of Translational Medicine, Universidad Católica del Maule, Chile. Her research centers on ion channels in cancer, with a focus on hyperpolarization-activated cyclic nucleotide-gated (HCN) channels as emerging therapeutic targets. She investigates the design of novel pharmacological strategies, including salt formation approaches to optimize drug physicochemical properties and biological activity. Her work also addresses endothelial senescence, platelet activation, and thrombotic risk associated with anticancer therapies. Her research integrates pharmacology, molecular biology, and translational approaches aimed at developing innovative therapeutic strategies.

Wu Jing, male, was born in April 1993, He holds a doctoral degree and currently works as a postdoctoral in the Medicinal bioinformatic center, Shanghai Jiaotong University. His research direction focuses on systematically elaborating the molecular characteristic map of diseases through multi-omics analysis methods, designing new target drugs for diseases and developing related drug design methods. He has published several representative papers, including "IDDB: a comprehensive resource featuring genes, variants and characteristics associated with infertility" published in Nucleic Acids Research in 2021 (co-authored with Jing Wu, Danjun Li, et al., Volume 49, Issue D1, Pages 1218-1224) and "Chemical and biological study of aplysiatoxin derivatives showing inhibition of potassium channel Kv1.5" published in RSC Advances in 2019 (co-authored with Yanghua Tang, Jing Wu, et al., Volume 9, Issue 14, Page 759).

Zhao Pengfei, MD, PhD, is a licensed pharmacist at the Second Affiliated Hospital of Zhejiang University School of Medicine. His primary research interests include pharmacokinetic studies and developing novel drug delivery systems.

Dongzheng Liu is a PhD candidate at the NICM Health Research Institute, Western Sydney University. His research focuses on plant-derived extracellular vesicles, with emphasis on extraction, purification, characterisation, omics profiling and biological activity evaluation. His current work investigates extracellular vesicles derived from Australian native botanicals and explores their molecular cargo, pharmacological relevance and potential biomedical applications. His broader research interests include natural products, extracellular vesicle biology and translational pharmacology.

Dr Arlene Taylor is an independent consultant with interests in precision medicine, pharmacogenomics, and evidence-based solutions that improve health (and other) outcomes for all members of society. With a background in clinical medicine, and extensive experience in associated fields, Dr Taylor has committed herself to applying her skills to create meaningful change.